Clinical Trials Logo

Alcoholic Liver Cirrhosis clinical trials

View clinical trials related to Alcoholic Liver Cirrhosis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03838250 Recruiting - Clinical trials for Alcoholic Liver Cirrhosis

Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC

Start date: June 20, 2019
Phase: Phase 1
Study type: Interventional

This study is to evaluate the safety and efficacy of a single dose of Cellgram™ delivered via hepatic artery in patients with decompensated alcoholic liver cirrhosis.

NCT ID: NCT01741090 Recruiting - Clinical trials for Alcoholic Liver Cirrhosis

The Effectiveness and Safety for Mesenchymal Stem Cell for Alcoholic Liver Cirrhosis

Start date: September 2009
Phase: Phase 2
Study type: Interventional

Background & Aim: Bone marrow derived mesenchymal stem cells (BM-MSCs) have capacity to differentiate into hepatocytes and anti-fibrotic effect in the experimental model. No study was done in humans with alcoholic liver cirrhosis. The researchers investigated the anti-fibrotic effect of BM-MSCs in alcoholic cirrhosis as Phase II clinical study. Methods: Eleven alcoholic cirrhosis patients (M:F = 10:1) with Child-Pugh's class B and maintenance of alcohol abstinence at least 2 months were enrolled. At baseline, all patients received liver biopsy, hepatic venous pressure gradient (HVPG) measurement and serologic tests. BM-MSCs were isolated from each patient's BM and amplified for one month and injected two times at 4, 8week through Rt. hepatic artery. 5x106cells/mL of BM-MSCs were injected in each session. Follow up biopsy, HVPG and relative expression of tissue transforming growth factor-1 (TGF-β1), α smooth muscle actin (α-SMA) and collagen-1 by real time RT PCR were measured after 12weeks from 2nd BM-MSC injection. The primary outcome was improvement in patients' histology Aim : The researchers aimed to evaluate safety and effectiveness of new therapy with bone marrow derived autologous mesenchymal stem cell for hepatic failure caused by alcoholic liver cirrhosis.

NCT ID: NCT00239096 Recruiting - Ascites Clinical Trials

Prevention of Decompensation in Liver Cirrhosis

Start date: September 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether losartan, an angiotensin II blocker prevents the sodium retention in patients with liver cirrhosis and by that reduces the fluid retention. Moreover is the purpose to asses whether losartan is antifibrotic.